{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:01:52Z","timestamp":1789070512740,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T00:00:00Z","timestamp":1530921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"St. Michael's Hospital Foundation"},{"name":"the Canada Research Chair\u2019s Program"},{"name":"the Canadian Institute of Heart and circulatory research"},{"name":"the Ministry of Ontario"},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12933-018-0741-9","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T03:42:36Z","timestamp":1530934956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Dual inhibition of sodium\u2013glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction"],"prefix":"10.1186","volume":"17","author":[{"given":"Kim A.","family":"Connelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8951-4478","authenticated-orcid":false,"given":"Richard E.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,7]]},"reference":[{"key":"741_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med."},{"issue":"7","key":"741_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"9","key":"741_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","volume":"20","author":"P Song","year":"2016","unstructured":"Song P, Onishi A, Koepsell H, Vallon V. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets. 2016;20(9):1109\u201325.","journal-title":"Expert Opin Ther Targets"},{"issue":"9","key":"741_CR4","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"I Vrhovac","year":"2015","unstructured":"Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, Radovic N, Jadrijevic S, Aleksic I, Walles T, et al. Localizations of Na(+)-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467(9):1881\u201398.","journal-title":"Pflugers Arch"},{"issue":"2","key":"741_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diab Ther. 2010;1(2):57\u201392.","journal-title":"Diab Ther"},{"issue":"5","key":"741_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512\u20137.","journal-title":"Nat Med"},{"key":"741_CR7","doi-asserted-by":"publisher","first-page":"41166","DOI":"10.1038\/srep41166","volume":"7","author":"A Steenbergen Van","year":"2017","unstructured":"Van Steenbergen A, Balteau M, Ginion A, Ferte L, Battault S, Ravenstein CM, Balligand JL, Daskalopoulos EP, Gilon P, Despa F, et al. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep. 2017;7:41166.","journal-title":"Sci Rep"},{"issue":"1","key":"741_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207\u201358.","journal-title":"Physiol Rev"},{"issue":"2","key":"741_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/cvr\/cvn116","volume":"79","author":"RW Schwenk","year":"2008","unstructured":"Schwenk RW, Luiken JJ, Bonen A, Glatz JF. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res. 2008;79(2):249\u201358.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"741_CR10","doi-asserted-by":"publisher","first-page":"e0130605","DOI":"10.1371\/journal.pone.0130605","volume":"10","author":"Y Kashiwagi","year":"2015","unstructured":"Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka TD, Ito K, Harada T, Takahashi H, Ikegami M, Anzawa R, Yoshimura M. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS ONE. 2015;10(6):e0130605.","journal-title":"PLoS ONE"},{"issue":"1","key":"741_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvp190","volume":"84","author":"SK Banerjee","year":"2009","unstructured":"Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84(1):111\u20138.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"741_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou L, Cryan EV, D\u2019Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90(2):339\u201346.","journal-title":"J Cell Biochem"},{"issue":"26","key":"741_CR13","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1021\/jm990175n","volume":"42","author":"K Tsujihara","year":"1999","unstructured":"Tsujihara K, Hongu M, Saito K, Kawanishi H, Kuriyama K, Matsumoto M, Oku A, Ueta K, Tsuda M, Saito A. Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4\u2032-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem. 1999;42(26):5311\u201324.","journal-title":"J Med Chem"},{"issue":"9","key":"741_CR14","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","volume":"48","author":"A Oku","year":"1999","unstructured":"Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, et al. T-1095, an inhibitor of renal Na+\u2009-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48(9):1794\u2013800.","journal-title":"Diabetes"},{"issue":"4","key":"741_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1161\/01.RES.44.4.503","volume":"44","author":"MA Pfeffer","year":"1979","unstructured":"Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res. 1979;44(4):503\u201312.","journal-title":"Circ Res"},{"issue":"20","key":"741_CR16","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.2174\/0929867043364360","volume":"11","author":"T Asano","year":"2004","unstructured":"Asano T, Ogihara T, Katagiri H, Sakoda H, Ono H, Fujishiro M, Anai M, Kurihara H, Uchijima Y. Glucose transporter and Na+\/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr Med Chem. 2004;11(20):2717\u201324.","journal-title":"Curr Med Chem"},{"issue":"1","key":"741_CR17","doi-asserted-by":"publisher","first-page":"e0144640","DOI":"10.1371\/journal.pone.0144640","volume":"11","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Thai K, Kepecs DM, Gilbert RE. Sodium\u2013glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS ONE. 2016;11(1):e0144640.","journal-title":"PLoS ONE"},{"issue":"6","key":"741_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723\u20139.","journal-title":"Diabetes"},{"issue":"8","key":"741_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/meta.2000.7729","volume":"49","author":"T Adachi","year":"2000","unstructured":"Adachi T, Yasuda K, Okamoto Y, Shihara N, Oku A, Ueta K, Kitamura K, Saito A, Iwakura I, Yamada Y, et al. T-1095, a renal Na+\u2009-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism. 2000;49(8):990\u20135.","journal-title":"Metabolism"},{"issue":"2","key":"741_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.yjmcc.2005.03.008","volume":"39","author":"AJ Boyle","year":"2005","unstructured":"Boyle AJ, Kelly DJ, Zhang Y, Cox AJ, Gow RM, Way K, Itescu S, Krum H, Gilbert RE. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol. 2005;39(2):213\u201321.","journal-title":"J Mol Cell Cardiol"},{"issue":"5","key":"741_CR21","doi-asserted-by":"publisher","first-page":"H2049","DOI":"10.1152\/ajpheart.00393.2004","volume":"287","author":"EE Morgan","year":"2004","unstructured":"Morgan EE, Faulx MD, McElfresh TA, Kung TA, Zawaneh MS, Stanley WC, Chandler MP, Hoit BD. Validation of echocardiographic methods for assessing left ventricular dysfunction in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2004;287(5):H2049\u201353.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"741_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bbrc.2005.12.198","volume":"341","author":"T Ramunddal","year":"2006","unstructured":"Ramunddal T, Lorentzon M, Omerovic E. Decreased mortality in a rat model of acute postinfarction heart failure. Biochem Biophys Res Commun. 2006;341(2):459\u201363.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"741_CR23","first-page":"H941","volume":"243","author":"FC Yin","year":"1982","unstructured":"Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML, Lakatta EG. Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. Am J Physiol. 1982;243(6):H941\u20137.","journal-title":"Am J Physiol"},{"issue":"5","key":"741_CR24","doi-asserted-by":"publisher","first-page":"H1415","DOI":"10.1152\/ajpheart.01048.2009","volume":"298","author":"SM Tan","year":"2010","unstructured":"Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol. 2010;298(5):H1415\u201325.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"741_CR25","doi-asserted-by":"publisher","first-page":"H1699","DOI":"10.1152\/ajpheart.00577.2005","volume":"290","author":"KA Connelly","year":"2006","unstructured":"Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol. 2006;290(4):H1699\u2013705.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"741_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/01.CIR.55.4.613","volume":"55","author":"RB Devereux","year":"1977","unstructured":"Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613\u20138.","journal-title":"Circulation"},{"issue":"1","key":"741_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1\u201339.","journal-title":"J Am Soc Echocardiogr."},{"issue":"13","key":"741_CR28","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1161\/01.CIR.0000012943.91101.D7","volume":"105","author":"G Derumeaux","year":"2002","unstructured":"Derumeaux G, Mulder P, Richard V, Chagraoui A, Nafeh C, Bauer F, Henry JP, Thuillez C. Tissue Doppler imaging differentiates physiological from pathological pressure-overload left ventricular hypertrophy in rats. Circulation. 2002;105(13):1602\u20138.","journal-title":"Circulation"},{"issue":"1","key":"741_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajpath.2016.09.016","volume":"187","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Connelly KA, Thai K, Wu X, Kapus A, Kepecs D, Gilbert RE. Sirtuin 1 activation reduces transforming growth factor-beta1-induced fibrogenesis and affords organ protection in a model of progressive, experimental kidney and associated cardiac disease. Am J Pathol. 2017;187(1):80\u201390.","journal-title":"Am J Pathol"},{"issue":"5","key":"741_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/1755-5922.12005","volume":"31","author":"KA Connelly","year":"2013","unstructured":"Connelly KA, Zhang Y, Advani A, Advani SL, Thai K, Yuen DA, Gilbert RE. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther. 2013;31(5):259\u201367.","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"741_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1161\/CIRCHEARTFAILURE.108.765750","volume":"2","author":"KA Connelly","year":"2009","unstructured":"Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ, Thai K, Krum H, Gilbert RE. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail. 2009;2(2):129\u201337.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"741_CR32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/HJH.0b013e3283462674","volume":"29","author":"KA Connelly","year":"2011","unstructured":"Connelly KA, Advani A, Kim S, Advani SL, Zhang M, White KE, Kim YM, Parker C, Thai K, Krum H, et al. The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. J Hypertens. 2011;29(6):1175\u201384.","journal-title":"J Hypertens"},{"issue":"7","key":"741_CR33","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.2337\/db12-1770","volume":"63","author":"H Kosanam","year":"2014","unstructured":"Kosanam H, Thai K, Zhang Y, Advani A, Connelly KA, Diamandis EP, Gilbert RE. Diabetes induces lysine acetylation of intermediary metabolism enzymes in the kidney. Diabetes. 2014;63(7):2432\u20139.","journal-title":"Diabetes"},{"issue":"2","key":"741_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cardiores.2007.06.022","volume":"76","author":"KA Connelly","year":"2007","unstructured":"Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res. 2007;76(2):280\u201391.","journal-title":"Cardiovasc Res"},{"issue":"9507","key":"741_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0140-6736(06)68074-4","volume":"367","author":"LH Opie","year":"2006","unstructured":"Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006;367(9507):356\u201367.","journal-title":"Lancet"},{"issue":"7 Pt B","key":"741_CR36","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.bbamcr.2016.02.011","volume":"1863","author":"P Mirtschink","year":"2016","unstructured":"Mirtschink P, Krek W. Hypoxia-driven glycolytic and fructolytic metabolic programs: pivotal to hypertrophic heart disease. Biochim Biophys Acta. 2016;1863(7 Pt B):1822\u20138.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"741_CR37","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.yjmcc.2010.06.003","volume":"49","author":"SK Banerjee","year":"2010","unstructured":"Banerjee SK, Wang DW, Alzamora R, Huang XN, Pastor-Soler NM, Hallows KR, McGaffin KR, Ahmad F. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J Mol Cell Cardiol. 2010;49(4):683\u201392.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"741_CR38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bbrc.2016.02.016","volume":"472","author":"A Kanwal","year":"2016","unstructured":"Kanwal A, Nizami HL, Mallapudi S, Putcha UK, Mohan GK, Banerjee SK. Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia-reperfusion injury. Biochem Biophys Res Commun. 2016;472(2):392\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"741_CR39","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1161\/CIRCULATIONAHA.114.013895","volume":"131","author":"B Crozatier","year":"2015","unstructured":"Crozatier B, Ventura-Clapier R. Inhibition of hypertrophy, per se, may not be a good therapeutic strategy in ventricular pressure overload: other approaches could be more beneficial. Circulation. 2015;131(16):1448\u201357.","journal-title":"Circulation"},{"issue":"6","key":"741_CR40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1161\/01.RES.84.6.735","volume":"84","author":"T Meguro","year":"1999","unstructured":"Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999;84(6):735\u201340.","journal-title":"Circ Res"},{"issue":"5","key":"741_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1172\/JCI6713","volume":"104","author":"JH Rogers","year":"1999","unstructured":"Rogers JH, Tamirisa P, Kovacs A, Weinheimer C, Courtois M, Blumer KJ, Kelly DP, Muslin AJ. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest. 1999;104(5):567\u201376.","journal-title":"J Clin Invest"},{"issue":"1","key":"741_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nm805","volume":"9","author":"M Brancaccio","year":"2003","unstructured":"Brancaccio M, Fratta L, Notte A, Hirsch E, Poulet R, Guazzone S, De Acetis M, Vecchione C, Marino G, Altruda F, et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med. 2003;9(1):68\u201375.","journal-title":"Nat Med"},{"issue":"5","key":"741_CR43","doi-asserted-by":"publisher","first-page":"H1814","DOI":"10.1152\/ajpheart.00449.2009","volume":"297","author":"RJ Gelpi","year":"2009","unstructured":"Gelpi RJ, Gao S, Zhai P, Yan L, Hong C, Danridge LM, Ge H, Maejima Y, Donato M, Yokota M, et al. Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload. Am J Physiol Heart Circ Physiol. 2009;297(5):H1814\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"741_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1152\/physiolgenomics.00061.2005","volume":"23","author":"BA Rothermel","year":"2005","unstructured":"Rothermel BA, Berenji K, Tannous P, Kutschke W, Dey A, Nolan B, Yoo KD, Demetroulis E, Gimbel M, Cabuay B, et al. Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure. Physiol Genomics. 2005;23(1):18\u201327.","journal-title":"Physiol Genomics"},{"issue":"15","key":"741_CR45","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","volume":"71","author":"A Gonzalez","year":"2018","unstructured":"Gonzalez A, Schelbert EB, Diez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71(15):1696\u2013706.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"741_CR46","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/phar.1303","volume":"33","author":"S Riser Taylor","year":"2013","unstructured":"Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy. 2013;33(9):984\u201399.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"741_CR47","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2337\/dc12-2391","volume":"36","author":"D Polidori","year":"2013","unstructured":"Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154\u201361.","journal-title":"Diabetes Care"},{"issue":"7","key":"741_CR48","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao EC, Henry RR. SGLT2 inhibition\u2014a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551\u20139.","journal-title":"Nat Rev Drug Discov."},{"issue":"11","key":"741_CR49","doi-asserted-by":"publisher","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","volume":"308","author":"RL Dobbins","year":"2015","unstructured":"Dobbins RL, Greenway FL, Chen L, Liu Y, Breed SL, Andrews SM, Wald JA, Walker A, Smith CD. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol. 2015;308(11):G946\u201354.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"9982","key":"741_CR50","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","volume":"385","author":"RE Gilbert","year":"2015","unstructured":"Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385(9982):2107\u201317.","journal-title":"Lancet"},{"key":"741_CR51","unstructured":"Kosiborod M, Cavender MA, Norhammar A, Wilding J, Khunti K. lower rates of hospitalization for heart failure and all-cause death in new users of sglt2 inhibitors: the CVD-REAL study. In: 66th scientific session of the American College of Cardiology. Washington, DC; 2017 (Abstract 415\u2013414)"},{"issue":"11","key":"741_CR52","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJMc1600140","volume":"374","author":"B Zinman","year":"2016","unstructured":"Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094.","journal-title":"N Engl J Med"},{"issue":"1","key":"741_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"H Kusaka","year":"2016","unstructured":"Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157.","journal-title":"Cardiovasc Diabetol"},{"key":"741_CR54","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"741_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"741_CR56","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.metabol.2009.10.025","volume":"59","author":"D Lewinski von","year":"2010","unstructured":"von Lewinski D, Rainer PP, Gasser R, Huber MS, Khafaga M, Wilhelm B, Haas T, Machler H, Rossl U, Pieske B. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism. 2010;59(7):1020\u20138.","journal-title":"Metabolism"},{"issue":"17","key":"741_CR57","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643\u201358.","journal-title":"Circulation"},{"issue":"11","key":"741_CR58","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1002\/jps.23302","volume":"101","author":"K Yamaguchi","year":"2012","unstructured":"Yamaguchi K, Kato M, Ozawa K, Kawai T, Yata T, Aso Y, Ishigai M, Ikeda S. Pharmacokinetic and pharmacodynamic modeling for the effect of sodium\u2013glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db\/db mice. J Pharm Sci. 2012;101(11):4347\u201356.","journal-title":"J Pharm Sci"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0741-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-018-0741-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0741-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T16:44:09Z","timestamp":1569257049000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0741-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,7]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0741-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,7]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"99"}}